The 36-month beta value for OLMA is at 2.11. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for OLMA is 48.61M, and currently, shorts hold a 18.46% of that float. The average trading volume for OLMA on May 10, 2024 was 810.26K shares.
OLMA) stock’s latest price update
Olema Pharmaceuticals Inc (NASDAQ: OLMA)’s stock price has decreased by -9.31 compared to its previous closing price of 10.85. However, the company has seen a -2.28% decrease in its stock price over the last five trading sessions. GlobeNewsWire reported 2024-05-01 that SAN FRANCISCO, May 01, 2024 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that its management team will participate in the following upcoming investor conferences:
OLMA’s Market Performance
Olema Pharmaceuticals Inc (OLMA) has seen a -2.28% fall in stock performance for the week, with a -10.05% decline in the past month and a -35.48% plunge in the past quarter. The volatility ratio for the week is 7.96%, and the volatility levels for the past 30 days are at 6.92% for OLMA. The simple moving average for the past 20 days is -5.78% for OLMA’s stock, with a -19.34% simple moving average for the past 200 days.
Analysts’ Opinion of OLMA
Many brokerage firms have already submitted their reports for OLMA stocks, with Goldman repeating the rating for OLMA by listing it as a “Buy.” The predicted price for OLMA in the upcoming period, according to Goldman is $24 based on the research report published on April 02, 2024 of the current year 2024.
Citigroup, on the other hand, stated in their research note that they expect to see OLMA reach a price target of $20. The rating they have provided for OLMA stocks is “Buy” according to the report published on January 30th, 2024.
Oppenheimer gave a rating of “Outperform” to OLMA, setting the target price at $21 in the report published on July 21st of the previous year.
OLMA Trading at -13.51% from the 50-Day Moving Average
After a stumble in the market that brought OLMA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -44.69% of loss for the given period.
Volatility was left at 6.92%, however, over the last 30 days, the volatility rate increased by 7.96%, as shares sank -14.81% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -24.13% lower at present.
During the last 5 trading sessions, OLMA fell by -2.28%, which changed the moving average for the period of 200-days by +12.84% in comparison to the 20-day moving average, which settled at $10.36. In addition, Olema Pharmaceuticals Inc saw -29.86% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at OLMA starting from Harmon Cyrus, who sale 5,000 shares at the price of $10.92 back on May 06 ’24. After this action, Harmon Cyrus now owns 806,283 shares of Olema Pharmaceuticals Inc, valued at $54,600 using the latest closing price.
Harmon Cyrus, the Director of Olema Pharmaceuticals Inc, sale 15,000 shares at $9.51 during a trade that took place back on Apr 30 ’24, which means that Harmon Cyrus is holding 811,283 shares at $142,650 based on the most recent closing price.
Stock Fundamentals for OLMA
The total capital return value is set at -0.41. Equity return is now at value -48.31, with -43.24 for asset returns.
Based on Olema Pharmaceuticals Inc (OLMA), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -34.64. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is 79.76.
Currently, EBITDA for the company is -104.58 million with net debt to EBITDA at 0.63. The liquidity ratio also appears to be rather interesting for investors as it stands at 9.61.
Conclusion
In conclusion, Olema Pharmaceuticals Inc (OLMA) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
